Universal Ibogaine Inc.
IBOGF
$0.065
-$0.005-7.14%
| 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 395.50K | 436.60K | 475.90K | 420.10K | 316.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 395.50K | 436.60K | 475.90K | 420.10K | 316.20K |
| Cost of Revenue | 331.00K | 306.90K | 340.10K | 260.70K | 266.00K |
| Gross Profit | 64.50K | 129.70K | 135.80K | 159.40K | 50.30K |
| SG&A Expenses | 325.10K | 207.20K | 194.20K | 116.30K | 306.20K |
| Depreciation & Amortization | 59.30K | 60.60K | 61.70K | 65.90K | 53.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 715.30K | 574.70K | 596.00K | 442.90K | 625.60K |
| Operating Income | -319.80K | -138.10K | -120.10K | -22.80K | -309.30K |
| Income Before Tax | -635.50K | -164.60K | -153.10K | -201.60K | -359.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -635.50K | -164.60K | -153.10K | -201.60K | -359.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -635.50K | -164.60K | -153.10K | -201.60K | -359.30K |
| EBIT | -319.80K | -138.10K | -120.10K | -22.80K | -309.30K |
| EBITDA | -260.60K | -77.50K | -58.40K | 43.10K | -255.90K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 284.45M | 191.79M | 191.77M | 191.87M | 191.49M |
| Average Diluted Shares Outstanding | 284.45M | 191.79M | 191.77M | 191.87M | 191.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
